NASDAQ:DMTX - Dimension Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.95 0.00 (0.00 %)
(As of 06/22/2018 01:04 AM ET)
Previous Close$5.95
Today's Range$5.95 - $5.95
52-Week Range$1.05 - $6.10
VolumeN/A
Average Volume150,214 shs
Market Capitalization$149.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Dimension Therapeutics logoDimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Receive DMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for DMTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:DMTX
CUSIPN/A
Phone+1-617-4010011

Debt

Debt-to-Equity Ratio0.14
Current Ratio2.01
Quick Ratio3.33

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.47 million
Price / Sales13.08
Cash FlowN/A
Price / CashN/A
Book Value$0.80 per share
Price / Book7.44

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-49,000,000.00
Net Margins-378.28%
Return on Equity-240.95%
Return on Assets-118.91%

Miscellaneous

Employees74
Outstanding Shares25,210,000

Dimension Therapeutics (NASDAQ:DMTX) Frequently Asked Questions

What is Dimension Therapeutics' stock symbol?

Dimension Therapeutics trades on the NASDAQ under the ticker symbol "DMTX."

How were Dimension Therapeutics' earnings last quarter?

Dimension Therapeutics Inc (NASDAQ:DMTX) released its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.20. The biotechnology company earned $4.48 million during the quarter. Dimension Therapeutics had a negative net margin of 378.28% and a negative return on equity of 240.95%. View Dimension Therapeutics' Earnings History.

What price target have analysts set for DMTX?

4 equities research analysts have issued 1-year price targets for Dimension Therapeutics' shares. Their forecasts range from $3.41 to $6.00. On average, they anticipate Dimension Therapeutics' stock price to reach $5.1367 in the next year. View Analyst Ratings for Dimension Therapeutics.

What are Wall Street analysts saying about Dimension Therapeutics stock?

Here are some recent quotes from research analysts about Dimension Therapeutics stock:
  • 1. Chardan Capital analysts commented, "We believe 2017 has been an even better year fundamentally, on the expansion of breakthrough results, the first 3 GT approvals in the US, sector late-stage momentum, sound safety, and other considerations below. We now make uniQure (Buy) a Chardan Top Pick for 2018 and a Chardan Top Pick in Gene Therapy for 2018." (12/22/2017)
  • 2. According to Zacks Investment Research, "Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. " (7/10/2017)

Who are Dimension Therapeutics' key executives?

Dimension Therapeutics' management team includes the folowing people:
  • Georges Gemayel Ph.D., Chairman of the Board (Age 56)
  • Annalisa M. Jenkins, President, Chief Executive Officer, Director (Age 52)
  • Mary T. Thistle, Principal Financial and Accounting Officer, Chief Operating Officer (Age 57)
  • Samuel C. Wadsworth Ph.D., Chief Scientific Officer (Age 68)
  • Eric Crombez M.D., Chief Medical Officer (Age 44)
  • John Hohneker, Director (Age 57)
  • Alan B. Colowick M.D., Independent Director (Age 54)
  • Michael Dybbs Ph.D., Independent Director (Age 42)
  • George V. Migausky, Independent Director (Age 62)
  • Arlene M. Morris, Independent Director (Age 65)

Has Dimension Therapeutics been receiving favorable news coverage?

News coverage about DMTX stock has been trending somewhat negative recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dimension Therapeutics earned a coverage optimism score of -0.06 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 44.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Dimension Therapeutics?

Shares of DMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dimension Therapeutics' stock price today?

One share of DMTX stock can currently be purchased for approximately $5.95.

How big of a company is Dimension Therapeutics?

Dimension Therapeutics has a market capitalization of $149.06 million and generates $11.47 million in revenue each year. Dimension Therapeutics employs 74 workers across the globe.

How can I contact Dimension Therapeutics?

Dimension Therapeutics' mailing address is 840 Memorial Dr Ste 4, CAMBRIDGE, MA 02139-3771, United States. The biotechnology company can be reached via phone at +1-617-4010011.


MarketBeat Community Rating for Dimension Therapeutics (DMTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about Dimension Therapeutics and other stocks. Vote "Outperform" if you believe DMTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.